Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy

被引:14
作者
Poole, Chris D. [1 ]
Bannister, Christian A. [1 ]
Andreasen, Jakob Norgaard [2 ]
Andersen, Jens Strodl [2 ]
Currie, Craig J. [1 ]
机构
[1] Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales
[2] ALK, Horsholm, Denmark
基金
英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; RHINITIS; CONJUNCTIVITIS; PREVALENCE; SEVERITY; TABLETS; BURDEN; MODELS; IMPACT; COST;
D O I
10.1186/1477-7525-12-99
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis (ARC) but its impact on general health-related utility has not been characterised for the purposes of economic evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass immunotherapy tablet (GRAZAX (R), 75,000 SQ-T/2,800 BAU, ALK, Denmark). Methods: Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of GRAZAX (R). Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and medication use. Results: DSS and DMS were the principal predictors of 'perfect' health (EQ-5D = 1.000; binomial) and 'imperfect' health (EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of 'perfect' health (EQ-5D = 1.000) by 27% and 16% respectively, and reduced 'imperfect' health by 0.17 and 0.13, respectively. Gender remained the only other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX (R) was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX (R) = 0.938 units (95% CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period. Conclusions: ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs observed for GRAZAX (R) may not fully describe the health benefits of this treatment, suggesting that economic modelling may be conservative.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Health-related quality of life measured using the EQ-5D–5L: South Australian population norms
    Nikki McCaffrey
    Billingsley Kaambwa
    David C. Currow
    Julie Ratcliffe
    Health and Quality of Life Outcomes, 14
  • [32] Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities
    Christine Blome
    Florian C. Beikert
    Stephan J. Rustenbach
    Matthias Augustin
    Archives of Dermatological Research, 2013, 305 : 197 - 204
  • [33] Perceptions of the General Public About Health-related Quality of Life and the EQ-5D Questionnaire: A Qualitative Study in Korea
    Ock, Minsu
    Pyo, Jeehee
    Jo, Min-Woo
    Herdman, Michael
    Luo, Nan
    JOURNAL OF PREVENTIVE MEDICINE & PUBLIC HEALTH, 2022, 55 (03) : 213 - 225
  • [34] Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis
    Stochl, J.
    Croudace, T.
    Perez, J.
    Birchwood, M.
    Lester, H.
    Marshall, M.
    Amos, T.
    Sharma, V.
    Fowler, D.
    Jones, P. B.
    QUALITY OF LIFE RESEARCH, 2013, 22 (05) : 1055 - 1063
  • [35] Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis
    J. Stochl
    T. Croudace
    J. Perez
    M. Birchwood
    H. Lester
    M. Marshall
    T. Amos
    V. Sharma
    D. Fowler
    P. B. Jones
    Quality of Life Research, 2013, 22 : 1055 - 1063
  • [36] A Bayesian Approach for Incorporating the EQ-5D Visual Analog Scale When Estimating the Health-Related Quality of Life
    Blythe, Robin
    White, Nicole
    Kularatna, Sanjeewa
    McPhail, Steven
    Barnett, Adrian
    VALUE IN HEALTH, 2022, 25 (09) : 1575 - 1581
  • [37] Preferences for health-related quality of life: do they vary by age? A systematic literature review on the EQ-5D measure
    Alabbad, Alhanouf
    Cochrane, Madeleine
    Mitchell, Paul Mark
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2025,
  • [38] A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D
    Huang, Rui
    Rao, Huiying
    Shang, Jia
    Chen, Hong
    Li, Jun
    Xie, Qing
    Gao, Zhiliang
    Wang, Lei
    Wei, Jia
    Jiang, Jianning
    Sun, Jian
    Jiang, Jiaji
    Wei, Lai
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2018, 16
  • [39] Changes in health-related quality of life (EQ-5D) dimensions associated with community-based musculoskeletal physiotherapy: a multi-centre analysis
    Caplan, N.
    Robson, H.
    Robson, A.
    Kelly, M.
    Wilkes, G.
    QUALITY OF LIFE RESEARCH, 2018, 27 (09) : 2373 - 2382
  • [40] Changes in health-related quality of life (EQ-5D) dimensions associated with community-based musculoskeletal physiotherapy: a multi-centre analysis
    N. Caplan
    H. Robson
    A. Robson
    M. Kelly
    G. Wilkes
    Quality of Life Research, 2018, 27 : 2373 - 2382